TCGA-CV-7103-01A-21R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.363242009
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- HEDGEHOG_SIGNALING+0.410
- UV_RESPONSE_DN+0.310
- TGF_BETA_SIGNALING+0.270
- ANGIOGENESIS+0.260
- WNT_BETA_CATENIN_SIGNALING+0.210
- APICAL_JUNCTION+0.180
- PANCREAS_BETA_CELLS+0.170
- COAGULATION+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.720
- INTERFERON_GAMMA_RESPONSE-0.620
- E2F_TARGETS-0.540
- MYC_TARGETS_V1-0.530
- MYC_TARGETS_V2-0.530
- G2M_CHECKPOINT-0.500
- TNFA_SIGNALING_VIA_NFKB-0.490
- ALLOGRAFT_REJECTION-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320067 | — | — | 0.901 |
| 2 | C3L-02165 | — | cohortA2 | 0.892 |
| 3 | SRR1313111 | — | A | 0.891 |
| 4 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.889 |
| 5 | TCGA-CQ-7072-01A-21R-A30B-07 | — | — | 0.875 |
| 6 | C3L-02834 | — | cohortA1 | 0.868 |
| 7 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.862 |
| 8 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.857 |
| 9 | TCGA-BH-A0EI-01A-11R-A115-07 | — | B | 0.856 |
| 10 | SRR8613781 | — | A | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.550 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| HYPOXIA | 0.040 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |